Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apadenoson for Myocardial Perfusion Imaging in Coronary Artery Disease
NCT01313572Phase 3Terminated
- Sponsor
- Forest Laboratories
- Start
- Aug 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of apadenoson in coronary artery disease (CAD), sponsored by Forest Laboratories. Started Aug 2011; status: terminated.
02
Drugs
apadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01313572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313572.